Editor-in-Chief: Godefridus J. Peters
Journal Rank: Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]
Submission to first decision: 63 days

Cancer Drug Resistance

Interview with Professor David A. Gewirtz: Exploring Breakthroughs in Cancer Drug Resistance and Treatment [Embedded Auto-Generated Subtitles]

NaN

Articles

Most Recent | Most Viewed | Most Downloaded

The role and clinical applications of exosomes in cancer drug resistance

Open Access Review DOI: 10.20517/cdr.2024.97 3 Nov 2024
Views: Downloads:
Download PDF

Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma

Open Access Review DOI: 10.20517/cdr.2024.54 30 Oct 2024
Views: Downloads:
Download PDF

NFE2L2 and ferroptosis resistance in cancer therapy

Open Access Review DOI: 10.20517/cdr.2024.123 24 Oct 2024
Views: Downloads:
Download PDF

The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models

Open Access Original Article DOI: 10.20517/cdr.2024.53 17 Oct 2024
Views: Downloads:
Download PDF

Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies

Open Access Review DOI: 10.20517/cdr.2024.67 14 Oct 2024
Views: Downloads:
Download PDF

Venetoclax resistance: mechanistic insights and future strategies

Open Access Review DOI: 10.20517/cdr.2021.125 5 May 2022
Views: Downloads:
Download PDF

Improving HER2 testing reproducibility in HER2-low breast cancer

Open Access Opinion DOI: 10.20517/cdr.2022.29 31 Aug 2022
Views: Downloads:
Download PDF

Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces

Open Access Review DOI: 10.20517/cdr.2022.20 1 Aug 2022
Views: Downloads:
Download PDF

Topic: Exosomes in Combating Cancer Drug Resistance

Submission Deadline: 15 Apr 2025

Published articles: 0

For Readers

Add your e-mail address to receive forthcoming Issues of this journal:

Articles Collection
On November 4, 2024, the editorial team sat down with Prof. David A. Gewirtz, a leading scientist in oncology research and an esteemed member of the journal’s Editorial Board.
On September 16, 2024, Stanford University and Elsevier jointly released the list of the world’s top 2% scientists.
The journal Cancer Drug Resistance has established a media partnership with the European Association for Cancer Research (EACR) and Boehringer Ingelheim for the upcoming EACR-Boehringer Ingelheim Conference: Drugging and Regulating the MAP Kinase Pathway.
We are pleased to announce that our journal, Cancer Drug Resistance (CDR), has obtained a new Impact Factor 2023 of 4.6, as reported by the Journal Citation Reports (JCR) released by Clarivate Analytics on June 20, 2024.
placing the journal in Q1 in the Pharmacology (medical) discipline

Interview with Professor David A. Gewirtz: Exploring Breakthroughs in Cancer Drug Resistance and Treatment [Embedded Auto-Generated Subtitles]

NaN

Topic: Exosomes in Combating Cancer Drug Resistance

Submission Deadline: 15 Apr 2025

Published articles: 0

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/